Skip to main content
. 2020 Nov 16;8(3):320–330. doi: 10.1016/j.gendis.2020.11.006

Table 1.

Synergetic effect of miR-182 and FOXO3a on predicting CRC progression.

FOXO3aa miR-182a
Low
% of Stage III/IV (n)
High
% of Stage III/IV (n)
Total
% of Stage III/IV (n)
Low 100% (6) 50% (4) 80% (10)
High 50% (4) 16.7% (6) 30% (10)
Total 80% (10) 30% (10) 55% (20)
a

Based on the cut-point of median relative expressions (2.02 for miR-182 and 0.21 for FOXO3a), Fisher's exact test P = 0.024 for testing four sub-groups with tumor stage.